NEW APPROACHES TO BRAIN TUMOR THERAPY CNS CONSORTIUM

这项建议的主要长期目标是改善 成人原发性脑肿瘤的治疗结果。这将是 通过促进I期和II期临床评估完成 前景看好的新制剂、生物方法、给药途径和 治疗中央区原发恶性肿瘤的临床试验设计 神经系统通过不断努力的新方法来达到 脑肿瘤治疗(NABTT)中枢神经系统联盟。 专门设计来结合和集中体验、资源、 和13个优秀医疗机构的能力(布朗 大学，哥伦比亚大学，埃默里大学，亨利·福特医院， 约翰霍普金斯大学，马萨诸塞州总医院，莫菲特癌症 西北大学[芝加哥]、阿拉巴马大学、 德克萨斯大学圣安东尼奥分校，宾夕法尼亚大学， 维克森林大学和华盛顿大学)将进行初选 脑瘤。参与机构有：(1)数量众多 成人原发性脑肿瘤患者，(2)专家 护理这些患者的多学科临床团队，(3) 广泛的临床和实验室资源；(4)数量惊人 持续的高质量、临床相关、同行审查和NIH资助 脑肿瘤临床和实验室研究项目，(5)国家 在肿瘤学、药理学、新药开发方面有公认的专业知识， I期和II期临床试验、神经外科和神经病理学，(6) 在生物统计学、数据管理和 协调多机构研究，以及(7)特殊情况 在临床护理和研究方面的卓越声誉。这个 财团通过定义明确且顺畅的 功能结构，强调临床试验设计，方案 开发、质量控制、研究监测和数据管理以及 分析。这项建议的次要长期目标是 利用该联盟共享人脑肿瘤标本以及 用于进行其他研究的其他临床和实验室数据 关于(1)原发脑肿瘤的基础生物学，(2) 原发脑肿瘤新疗法的神经药理学，以及(3) 改善成人初级脑疾病患者的护理和生活质量 肿瘤。这一目标将利用 参与机构与NABTT相关生物学研究 中心、NABTT药理学中心和NABTT工作和 科学委员会。

The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by fostering Phase I and II clinical evaluations of promising new agents, biologic approaches, routes of administration, and trial design in the treatment of primary malignancies of the central nervous system through the continued efforts the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium." This consortium is specifically designed to combine and focus the experience, resources, and capabilities of thirteen outstanding medical institutions (Brown University, Columbia University, Emory University, Henry Ford Hospital, Johns Hopkins University, Massachusetts General Hospital, Moffitt Cancer Center, Northwestern University [Chicago], the University of Alabama, the University of Texas at San Antonio, the University of Pennsylvania, Wake Forest University, and Washington University) to bear on primary brain tumors. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams caring for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology, (6) extensive expertise in biostatistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths with a well-defined and smoothly functioning structure, an emphasis on clinical trial design, protocol development, quality control, study monitoring, and data management and analysis. The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuro-pharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the participating institutions and the NABTT Correlative Biology Research Center, The NABTT Pharmacology Center, and The NABTT Working and Scientific Committees.